Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 29;7(12):635.
doi: 10.1038/s41408-017-0011-1.

Improved outcome for AML patients over the years 2000-2014

Sarah Bertoli  1   2   3 , Suzanne Tavitian  1 , Anne Huynh  1 , Cécile Borel  1 , Sarah Guenounou  1 , Isabelle Luquet  4 , Eric Delabesse  4 , Audrey Sarry  1 , Guy Laurent  1   2 , Michel Attal  1   2 , Françoise Huguet  1 , Emilie Bérard  5   6 , Christian Récher  7   8   9
Affiliations

Improved outcome for AML patients over the years 2000-2014

Sarah Bertoli et al. Blood Cancer J. .

Abstract

Few recent studies from registries have reported an improvement in overall survival of younger patients with acute myeloid leukemia (AML). However, reasons for this improvement are not defined. We analyzed the therapeutic course and outcome of 976 patients treated by intensive chemotherapy between 2000 and 2014. The number of patients receiving allogeneic stem cell transplantation in first or second response significantly increased over time whereas autologous transplantation was progressively abandoned. In the 513 younger patients, there were no differences in first complete response, induction failure, incidence of relapse, or non-relapse mortality over time. The period of time was significantly associated with a better overall survival especially in 2010-2014. The 2010-2014 period effect was still significant in multivariate analysis and was independent of allogeneic stem cell transplantation. In the 463 older patients, there was a significant interaction between the period and leukocytosis in multivariate analysis meaning that the 2010-2014 period had only an impact in patients with white blood cell count >50 giga/L for response and overall survival. Progresses have been made in each phase of the therapeutic course of younger AML patients resulting in survival improvement. In older patients, the outcome of hyperleukocytic patients has significantly improved in 2010-2014.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Overall survival (OS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) in first complete response in younger (<60 years) AML patients
Fig. 2
Fig. 2
a Overall survival in the whole cohort of AML patients ≥60 years b in patients ≥60 years with WBC ≤ 50 giga/L c and in patients ≥60 years with WBC > 50 giga/L
See this image and copyright information in PMC

References

    1. DeAngelo D. J., Stein E. M. & Ravandi F. Evolving therapies in acute myeloid leukemia: progress at last?Am. Soc. Clin. Oncol. Educ. Book35, e302–e312 (2016). - PubMed
    1. Sekeres M. A. & Steensma D. P. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J. Clin. Oncol.30, 4061–4063 (2012). - PubMed
    1. Dohner H., Weisdorf D. J. & Bloomfield C. D. Acute myeloid leukemia. N. Engl. J. Med.373, 1136–1152 (2015). - PubMed
    1. Ellison LF. Increasing survival from leukemia among adolescents and adults in Canada: a closer look. Health Rep. 2016;27:19–26. - PubMed
    1. Sant M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931–942. doi: 10.1016/S1470-2045(14)70282-7. - DOI - PubMed

Publication types